1 In situ transcriptional profile of a germinal center plasmablastic burst hints at an

2 unfavorable Diffuse Large B-cell Lymphoma subset.

- 3
- 4 Vincenzo L'Imperio^{1*}, Gaia Morello^{2*}, Valeria Cancila², Giorgio Bertolazzi², Saveria
- 5 Mazzara³, Beatrice Belmonte², Piera Balzarini⁴, Lilia Corral⁵, Arianna Di Napoli⁶, Fabio
- 6 Facchetti⁷, Fabio Pagni¹*, Claudio Tripodo^{2,8}*
- 7 ¹ Department of Medicine and Surgery, University of Milano-Bicocca, Pathology, San Gerardo
- 8 Hospital, Via G.B. Pergolesi 33, Monza, Italy.
- 9 ² Tumor Immunology Unit, Department of Sciences for Health Promotion and Mother-Child
- 10 Care "G. D'Alessandro", University of Palermo, Palermo, Italy.
- ³ Division of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy.
- ⁴ Department of Molecular and Translational Medicine, University of Brescia, Piazzale Spedali
- 13 Civili 1, 25123, Brescia, Italy.

14 ⁵ Centro Ricerca Tettamanti, Pediatric Clinic, University of Milan Bicocca, San Gerardo

- 15 Hospital/Fondazione MBBM, Monza, Italy.
- 16 ⁶ Pathology Unit, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
- ⁷ Pathology Unit, University of Brescia, Brescia, Italy.
- 18 ⁸ Tumor and Microenvironment Histopathology Unit, IFOM, the FIRC Institute of Molecular
- 19 Oncology, Milan, Italy.
- 20
- 21 * These Authors equally contributed

22

- 23 Correspondence:
- 24 Prof. Claudio Tripodo, Tumor Immunology Unit, University of Palermo, Corso Tukory
- 25 211, 90134, Palermo. Phone +3909123896211. Email: claudio.tripodo@unipa.it
- 26
- 27
- 28
- 29
- ____
- 30

31 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 Abstract

33 The germinal center (GC) reaction results in the selection of B-cells acquiring effector Ig 34 secreting ability by progressing towards plasmablastic differentiation. This transition is 35 associated with exclusion from the GC microenvironment. The aberrant expansion of 36 plasmablastic elements within the GC fringes configures an atypical condition, the biological 37 characteristics of which have not been defined yet. We investigated the in situ 38 immunophenotypical and transcriptional characteristics of a non-clonal germinotropic 39 expansion of plasmablastic elements (GEx) occurring in the tonsil of a young patient. 40 Compared to neighboring GC and peri-follicular regions, the GEx showed a distinctive 41 signature featuring key regulators of plasmacytic differentiation, cytokine signaling, and cell 42 metabolism. The GEx signature was tested in the setting of diffuse large B-cell lymphoma (DLBCL) as a prototypical model of lymphomagenesis encompassing transformation at 43 44 different stages of GC and post-GC functional differentiation. The signature outlined DLBCL 45 clusters with different overall survival, highlighting the negative prognostic significance of the overexpression of hallmark genes of this peculiar condition. 46

47

48 **Running title:** Spatial profiling of a germinotropic plasmablastic expansion

49

50 Keywords: digital spatial profiling, germinal center, plasmablast, diffuse large B-cell
51 lymphoma.

- 52
- 54

- 55
- 56

57 Introduction

58 Within secondary lymphoid organs immune cells display topographic compartmentalization 59 underlying functional commitment towards different stages of immune response induction and 60 regulation. In lymphoid follicles, germinal centers (GCs) represent a complex specialized 61 microenvironment sustaining B-cell proliferative bursts underlying somatic hypermutation and 62 class-switch recombination of immunoglobulin (Ig) genes, communication with T cell subsets 63 with helping function (Tfh), and interplay with specialized mesenchymal scaffolds (i.e. FDCs) 64 (1). These events play through the dynamical iteration of elements between the dark (DZ), 65 intermediate and light (LZ) zones of the GC (2), eventually resulting in the differentiation and 66 displacement from the GC of cells acquiring effector capabilities through the synthesis and 67 secretion of Igs (i.e. plasmablasts and plasma cells) (3). Alterations in the topographic 68 compartmentalization of GC and extra-GC populations in lymphoid tissues are commonly 69 observed in the setting of lymphoproliferative diseases, where the accumulation of cells with 70 morphological or immunophenotypical features conflicting with their topographic localization 71 represents a hallmark of histopathological analyses. This assumption reached its highest 72 expression with the introduction of a diffuse large B cell lymphoma (DLBCL) prognostic sub-73 classification based on the presumed cell-of-origin (COO), as determined by gene expression 74 profiling (GEP) (4-6).

We have investigated here an atypical germinotropic expansion of non-clonal, light-chain restricted B cells with plasmablastic features confined to a single enlarged GC structure in the tonsil of a young patient, through in situ immunolocalization analyses and high throughput digital spatial profiling. Comparing the features of the atypical germinotropic expansion (GEx) with those of topographically preserved DZ, LZ and peri-follicular (PERI) regions of interest (ROIs) we identified a unique transcriptomic profile of the GEx ROIs featuring the

81 overexpression of transcripts involved in plasmacytoid differentiation, cytokine signaling, and
 82 cell metabolism.

To probe the reflection of the identified transcriptional signature in a setting of B-cell lymphomatous transformation embracing the full spectrum of GC- and post-GC differentiation, the discriminative 20 genes were used to cluster a large cohort of diffuse large B-cell lymphoma (DLBCL) transcriptomic data. The GEx signature highlighted two clusters with different overall survival in DLBCL, where cases with the highest expression of GEx hallmark genes were characterized by poorer prognosis.

- 89
- 90

91 Materials and methods

92 *Clinical setting*

93 This study started from the incidental finding of the reactive germinotropic plasmablastic 94 expansion described in the Results section, in the tonsil of a young patient who underwent 95 tonsillectomy for clinical hypertrophy. Sample was obtained and handled according to the 96 Declaration of Helsinki. Informed consent for surgery and histopathological studies was 97 obtained from the legal representatives. The case was included in the study 05/2018 approved 98 by the University of Palermo Institutional Review Board.

99 Histological, immunohistochemical and molecular analyses

Tonsillar tissue has been formalin-fixed and paraffin-embedded (FFPE) and 3 μm thick sections have been stained with hematoxylin and eosin (H&E). IHC has been performed at the Pathology Department of ASST Monza, San Gerardo Hospital, Monza, Italy using a Dako Omnis platform (Dako, Denmark) using antibodies directed against CD20 (L26), CD3 (Polyclonal), Bcl2 (124), Bcl6 (PG-B6p), CD21, ki-67 (Mib-1), MUM1, CD10, CD30 (Ber-H2), CD138 (Mi15), HHV8 (13B10), kappa and lambda light chains. Double 106 immunohistochemistry has been performed for MUM1 and CD10 using 3-3'-diaminobenzidine 107 (DAB) and 3-amino-9-ethylcarbazole (AEC) as chromogens, respectively. In situ fluorescence 108 hybridization (FISH) study has been performed using a IRF4/DUSP22 (6p25) Break Apart kit 109 (Kreatech, Leica Biosystem, Germany) at the Pathology Department of Spedali Riuniti di 110 Brescia. Quantitative evaluation of immunophenotypical markers was performed by applying 111 the HALO image analysis software (v3.2.1851.229, Indica Labs) to regions selected on whole 112 slide digital scans acquired using an Aperio CS2 slide scanner with the ImageScope software 113 (v12.3.28013, Leica Biosystems, Germany). 114 Quantitative polymerase chain reaction (Q-PCR) to detect clonal immunoglobulin genes

115 rearrangement was performed after laser microdissection on H&E-stained slides, using an

- 116 LMD6 platform (Leica Microsystems, Germany).
- 117 Digital spatial profiling

118 The transcriptional landscape of 15 different spatially-resolved regions of interests (ROIs) of 119 the tonsil (5 peri/inter-follicular ROIs, 5 DZ and 5 LZ ROIs from morphologically normal 120 follicles) and 9 ROIs from the GEx was determined by Digital Spatial Profiling on slides 121 stained with CD271/NGFR (as an FDC marker to highlight the LZ) and CD20 (as a B-cell 122 marker). The 24 selected and segmented ROIs were profiled using a GeoMx Digital Spatial 123 Profiler (DSP) (NanoString, Seattle WA) as previously described (7), applying the Cancer 124 Transcriptome Atlas panel (https://www.nanostring.com/products/geomx-digital-spatialprofiler/geomx-rna-assays/geomx-cancer-transcriptome-atlas/) (Supplementary Table 1). 125 126 Bioinformatic Data Analysis

127 After quality check step, raw counts were normalized against the 75th percentile of signal from

- 128 their own ROI and normalized data were used to perform PCA using FactoMine R package.
- 129 For hierarchical clustering analysis of the ROIs the Euclidean distance metric across samples

130 was considered and complete aggregation method was used for building tree within the R131 package hclust.

132 Differential expression analyses were carried out by applying the moderated t-test using the 133 limma package (8); pairwise comparisons between GEx and DZ/LZ/Peri ROIs were 134 considered. Upregulated/downregulated genes were selected for subsequent analysis if their 135 expression values were found to exceed the threshold of 0.05 FWER (Bonferroni correction). 136 The spatial GEx signature was assessed in the following GEO datasets: GSE32918 (9) and 137 GSE117556 (10). First, samples with a low Pearson correlation coefficient with other samples 138 in the space of all genes for each separately dataset were removed as proposed by Kotlov et 139 al.(28). Probe sets were annotated using the annotation files from IlluminaHumanv4.db and 140 illumina Humanv3.db. When multiple probes were associated to the same we collapsed to the 141 average value. Next, the two transcriptomic datasets were combined and a quantile 142 normalization was performed using preprocess Core package. Furthermore, possible batch 143 effects were corrected with limma package and a PCA was considered to verify the effective 144 removal of the batch effects.

The clinical information for rGSE32918 cohort (9) was downloaded from GEO repository
while, forGSE117556 cohort was retrieved from the supplementary material of Sha et al (10).

After performing z-score, unsupervised hierarchical clustering analysis based on the GEx signature was applied to identify potential discriminative clusters based on Ward.D2 method on the Euclidean distance of z-score expression. Silhouette and the elbow methods, from the factoextra R package were employed to choose the optimal number of clusters. Differences in the total GEx signature expression inside clusters were evaluated using a Kolmogorov-Smirnov test on ECDFs. The Cox model has been fitted to estimate the relative risk of death between clusters. Before calculating the log-rank test and fitting the Cox model, the cox.pzh test has 154 been used to test the proportional hazard assumption. In order to directly evaluate the 155 association between patient survival time and expression of the GEx signature, we assessed a 156 quantile strategy to split patients into four groups. To analyze the prognostic value of GEx 157 signature, merged cohort was dichotomized into higher (GEx expression is greater than the 75th quantile) and lower groups (GEx expression is lower than the 25th quantile) whereas patients 158 159 with the GEx expression between the two extremes were excluded from the survival analysis. 160 Difference in patient characteristics was analyzed with the Fisher's exact test. 161 All statistical analyses were performed using R statistical software (v4.0.2, http://www.R-162 project.org). 163 Data Availability 164 Normalized gene expression data generated in the Digital Spatial Profiling experiment are 165 available in Supplementary Table 1 166 167 168 **Results** 169 Pathology of the tonsil 170 Histopathological analysis of the left tonsil from a young patient with clinical bilateral 171 hypertrophy revealed, in a background of lymphoid follicles with hyperplastic features and 172 preserved GC DZ, LZ and mantles, an isolated abnormal follicle with flattened mantle zone, 173 an enlarged GC, without evident DZ/LZ polarization, preservation of rare tingible body 174 macrophages, and populated by a predominance of monomorphic plasmacytoid cells with 175 immature morphology (Figure 1A). Quantitative immunophenotypical characterization of 176 reactive follicular and peri-follicular regions and of the atypical germinotropic plasmablasts

177 (GEx), highlighted conspicuous differences in the immune profile (Figure 1B-C). The reactive

178 preserved DZ and LZ of GCs were characterized by B cells with strong CD20 expression, dense 179 Ki-67 immunoreactivity (higher in the DZ), negativity for IRF4, except for scattered cells in a 180 background of CD10-expressing cells, Bcl-2 negativity, slight T-cell infiltration (denser in the 181 LZ), and no evidence of light chain restriction (Figure 1B-C). At contrast, the composition of the GEx displayed a CD20+ B cell phenotype, high Ki-67+ proliferative fraction, diffuse IRF4 182 183 cells co-expressing CD10, positivity with IRF4+ negativity for Bcl-2, and 184 immunophenotypical restriction for lambda light chain (Figure 1B-C). Most of the cells 185 populating the GEx also expressed CD138 in the absence of CD30, indicating partial 186 acquisition of a plasmablastic phenotype. Immunoistochemistry for HHV8 and in situ hybridization for EBER (EBV) proved negative (Supplementary Figure 1). On the basis of the 187 188 GEx lambda light chain restriction, analysis of the Ig light and heavy genes rearrangement was 189 performed on DNA extracted by laser microdissection of the GEx, which revealed a polyclonal 190 profile (Supplementary Figure 2). The strong and diffuse immunoreactivity of IRF4 and the 191 co-occurrence of IRF4/CD10 double-expressing elements prompted the analysis of IRF4 gene 192 rearrangement by fluorescence in situ hybridization (FISH), which did not reveal any 193 abnormality (Supplementary Figure 3), allowing to exclude an IRF4-rearranged lymphoma.

194

195 Digital Spatial Profiling of the GEx regions reveals a distinctive profile

The molecular profiles of non-malignant GC compartments can be exploited to probe GC microenvironment imprints in B-cell lymphomas with different degree of relationship with GC subpopulations, such as DLBCL, in which the COO has shown prognostic significance in the setting of standard chemo-immunotherapy regimens (7). We had the opportunity to probe the in situ transcriptional profile of a yet unexplored atypical configuration of a GC proliferative burst. Through the Nanostring GeoMx technology, the expression of 1824 genes from key cancer-associated transcriptional programs (Supplementary Table 1) was determined on 5 DZ,

203 5 LZ and 5 PERI ROIs selected from morphologically/phenotypically preserved 204 follicles/perifollicular areas, and on 9 GEx ROIs. We then asked whether GEx ROIs could be 205 defined by a specific gene signature; to this aim, principal component analysis (PCA) and 206 unsupervised hierarchical clustering were investigated. PCA revealed that ROIs segregated 207 according to their spatial classification, with PERI regions showing neatly separated profiles 208 from GC ROIs including DZ, LZ and GEx and GEx ROIs clustered together with other GC 209 regions, showing some degree of intermixing with LZ ROIs (Figure 2A). Consistently, 210 clustering analysis confirmed the same degree of relationship between the different ROIs 211 (Figure 2B). mRNA expression of the transcripts relative to the IHC markers evaluated for 212 quantitative immunopehnotypical analyses showed consistency with the protein expression 213 pattern (Supplementary Figure 4). Pairwise differential expression analysis performed on the 214 different ROIs allowed to identify candidate genes reflecting the distinctive profiles between 215 the GEx ROIs in comparison with DZ LZ and PERI ROIs (Figure 2C-F). Among the 20 genes, 216 17 were significantly upregulated in GEx ROIs, while 3 were downmodulated (Figure 2C-F). 217 GEx hallmark genes included, along with the plasma cell differentiation markers *PRDM1*, 218 IRF4, TNFRSF17 (BCMA) and CD9, genes involved in 2-oxoglutarate metabolism (GOT2, 219 IDH2), in IL17 pathway (IL17RB, HSP90B1) and cytokine signaling (RASAL1, LTB), in PI3K-220 Akt pathway (SGK1, BCL2L1), in lymphocyte activation (ADA, SCL7A5, FCRL2) and cell 221 surface regulation of immune activation (CD24, LILRB1), in cell adhesion (ANKRD28) and 222 response to abiotic (i.e. osmotic) stress (SLK1). Moreover, the long non-coding RNA FAM30 223 was also listed among the GEx hallmarks.

224

225 The GEx signature outlines a subset of DLBCL with unfavorable prognosis

226 To investigate whether the transcriptional hallmarks identified in the GEx ROIs could be traced

227 in the heterogeneous spectrum of B-cell malignant transformation recapitulated by DLBCL,

228 we applied the GEx gene signature to a harmonized dataset of 1147 DLBCL cases relative to 229 GSE32918 (9) and GSE117556 (10). Based on the expression of the GEx signature (19 protein-230 coding genes), DLBCL clustered into two main groups (Figure 3A), with the cluster 1 231 characterized by significantly different enrichment in ABC cases (Fisher exact test p-value < 232 10e-10) and significantly worst overall survival (Figure 3A-B, relative risk (RR) = 1.61, p-val 233 < 0.001). Since 17 out of the 20 GEx differential genes were overexpressed as compared with 234 DZ, LZ, and PERI ROIs, we comparatively analyzed DLBCL cases expressing high or low 235 levels of the GEx overexpressed genes focusing on the Q1 and Q4 quartiles of their cumulative 236 expression (Figure 3C). DLBCL cases characterized by highest (Q4) cumulative expression of 237 the GEx genes had a significantly poorer OS as compared with cases characterized by the 238 lowest expression (Q1) (Figure 3C, RR = 1.63, p-value = 0.002). The negative prognostic value of the GEx overexpressed genes was significant also when ABC DLBCL cases only were 239 240 considered (Figure 3D, RR = 1.79, p-val = 0.04), while it was lost in the GCB DLBCL subset 241 (Figure 3E, RR = 1.22, p-val = 0.37), suggesting that the genes positively characterizing GEx 242 ROIs underlie a specific biology related with the ABC COO, known to be enriched in clones 243 undergoing plasmablastic/plasmacytic commitment.

244

245 Discussion

Plasma cells (PCs) represent the final step of the functional differentiation process of the B lymphocyte, through the transition in short-living highly proliferative plasmablasts. The transition of B cells undergoing selection and refinement of their IG receptor in the GC reaction towards effectors capable of Ig secretion implies the acquisition of plasmablastic/plasmacytoid features within the GC microenvironment. The spatial localization of these functional and phenotypical intermediates is still poorly characterized and depends on the dynamical modulation of chemotactic receptor/ligand axes interweaving with BCR-controlled programs 253 (11). Proliferating cells with plasmablastic/plasmacytoid features accumulating within the GC 254 therefore represents an element of atypia even in the setting of non-clonal events, and little is 255 known about the *molecular signature* characterizing their transient state (12). In this report we 256 phenotypically and transcriptionally characterized an immunoglobulin light chain restricted 257 non-clonal atypical germinotropic expansion of plasmablastic cells, investigating differential 258 features emerging from the comparison with neighboring GC and extra-GC regions. The GEx 259 ROIs were characterized by the unique co-occurrence of IRF4 and CD10 expression, which 260 highlighted a transitory state engendered by IRF4 control of GC exit (13) and CD10 261 ectopeptidase retention that can be observed in DLBCL with plasmablastic differentiation (14). 262 On digital spatial profiling, a set of 20 genes were found differentially expressed in GEx ROIs 263 as compared with neighboring DZ, LZ and PERI ROIs. The discriminating signature resulted 264 positively enriched in the key transcription factors driving plasma cell differentiation IRF4 and 265 PRDM1, and included the B-cell differentiation receptor BCMA involved in the transduction 266 of trophic signals from APRIL and BAFF tumor necrosis factor superfamily ligands (15). Such 267 molecular features supportive of a plasmablastic phenotype were also supported by the downregulation of CD24, a signal transducer negatively modulated in response to BCR 268 269 activation and along plasmablastic transition (16). The GC localization of the plasmablastic 270 expansion found resonance in the overexpression of CD9. The tetraspanin CD9 has been 271 reported to mark a subset of B cells in the human GC characterized by plasmablastic 272 differentiation and Blimp1 (*PRDM1*) expression (17). These CD9+ GC B cells more efficiently 273 give rise to CD20-CD38+ plasmablasts as compared with their CD9- counterpart. Moreover, 274 in the murine setting, the efficient plasmablastic/plasmacytic differentiation of CD9+ B cells 275 is shared by non-GC B-cells endowed with prompt commitment to Ig-secreting effectors, such 276 as B1 B cells and marginal zone B-cells subsets (18). By applying the GEx differentially 277 expressed genes signature to DLBCL we aimed at investigating whether the atypical status of

278 non-clonal germinotropic plasmablastic expansion could be represented in the transcriptional 279 signature of a subset of DLBCL of either ABC or GCB COO. Previous reports described a 280 subset of ABC-DLBCL expressing PRDM1/BLIMP1 and demonstrated that loss of function 281 of this antigen is harbinger of a poor prognosis (19). Expression of IRF4/MUM1 is routinely 282 employed in the diagnostic setting for the distinction of non-GC subtypes based on 283 immunohistochemical algorithms (20). Moreover, specific subtypes of large B-cell lymphomas 284 characterized by IRF4 rearrangement have been recently described and recognized as 285 independent entities in the most recent WHO classification (21). We report additional 286 molecular markers potentially associated with plasmablastic commitment in the GC, including 287 the receptor of IL17B/IL25 IL17RB, the overexpression of which marks lymphoplasmacytic lymphomas with mutant MYD88^{L265P} and CXCR4^{WT} (22). In the GC setting, IL17B/IL25 288 289 signaling could enforce NF-KB activity (23) through TRAF6, which cooperation with CD40 290 signaling is required for B-cell affinity maturation and plasma cell differentiation (24). From 291 the genes positively and negatively characterizing GEx ROIs, no relevant clues emerge about 292 the mechanisms leading to the atypical GC retention and expansion of the plasmablastic 293 elements. Under normal conditions, the suppression of Bach2 and Pax5 transcripts, along with 294 the down-regulation of Bcl-6, IRF8 and PU-1 and the activation of BLIMP1 and MUM1/IRF4, 295 drive the development of PCs resulting from the GC reaction (1). Once their effector/memory 296 fate is established, B cells escape from the GCs through the suppression of the BCL-6-induced 297 "confinement factor" S1PR2 and the expression of pro-migratory receptors that are likely to be 298 involved in GC exit, such as EBI2 and S1PR1 (25). The downmodulation of lymphotoxin beta 299 transcript emerging from the GEx ROIs profiling can imply an impaired activation of the FDC 300 meshwork by resident elements (26) which would in turn impact on the maintenance of a 301 functional GC microenvironment licensing atypical plasmablastic expansion within the GC 302 contexture. Indeed, some cases of abrupt/florid follicular hyperplasia have been described in

303 which activated B cells are mainly localized in the GCs, partly twisting the normal follicular 304 architecture and even showing immunohistochemical light chain (oligoclonal) restriction, 305 leading to diagnostic concern for neoplasia (27). The evidence of a negative prognostic 306 significance of the GEx hallmark genes in a large harmonized dataset, which proved to be 307 significant in ABC but not in GCB cases, suggests that within the heterogeneous ABC COO, 308 in which specific genetic subgroups are enriched, GC-related proliferations of plasmablastic 309 elements could be represented. Genetic studies in such cases in which a dyscrasia between 310 cyto-architectural, phenotypical and topographic profile of a B-cell expansion with 311 plasmablastic/plasmacytic features may help in finding a link with specific genetic subsets of 312 DLBCL (28) and reconcile an ABC-COO with GC-like microenvironment features (29).

- 313
- 314

315 Acknowledgements

The Authors wish to acknowledge Prof. Maurilio Ponzoni for helpful discussion. This study has been supported by the Italian Foundation for Cancer Research (AIRC) through the IG-2018 22145 Investigator Grant to C.T.; 5x1000 22759 Grant to C.T.; and by the Italian Ministry of Education, University and Research (MIUR) grant 2017K7FSYB to C.T.

320

321

323 REFERENCES

| 324 325 326 | 1. | De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015 Mar;15(3):137-48. doi: 10.1038/nri3804. Epub 2015 Feb 6. PMID: 25656706; |
|-------------------|-----|---|
| 327 328 | | PMCID: PMC4399774. |
| 329 | 2. | Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. |
| 330 331 | | Immunity. 2007 Aug;27(2):190-202. doi: 10.1016/j.immuni.2007.07.009. PMID: 17723214; PMCID: PMC2242846. |
| 332 | | |
| 333 | 3. | Yam-Puc JC, Zhang L, Maqueda-Alfaro RA, Garcia-Ibanez L, Zhang Y, Davies J et al. |
| 334 335 | | Enhanced BCR signaling inflicts early plasmablast and germinal center B cell death. iScience 2021 Jap 7:24(2):102038 doi: 10.1016/j.jsci.2021.102038 PMID: |
| 336 | | 33532715: PMCID: PMC7822941 |
| 337 | | 55552,10,111010,1110,022,11 |
| 338 | 4. | Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types |
| 339 | | of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 |
| 340 | | Feb 3;403(6769):503-11. doi: 10.1038/35000501. PMID: 10676951. |
| 341 | 5 | Chanux P. Stowart C. Dunford AI Vim I. Komburov, A. Podd P.A. at al. Malagular |
| 343 | 5. | subtypes of diffuse large B cell lymphoma are associated with distinct nathogenic |
| 344 | | mechanisms and outcomes. Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591- |
| 345 | | 018-0016-8. Epub 2018 Apr 30. Erratum in: Nat Med. 2018 Aug;24(8):1292. Erratum |
| 346 | | in: Nat Med. 2018 Aug;24(8):1290-1291. PMID: 29713087; PMCID: PMC6613387. |
| 347 | 6 | |
| 348 | 6. | Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ et al. Genetics |
| 349 350 | | and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018 Apr 12:378(15):1396-1407 doi: 10.1056/NEIMoa1801445 PMID: 29641966: PMCID: |
| 351 | | PMC6010183. |
| 352 | | |
| 353 | 7. | Tripodo C, Zanardi F, Iannelli F, Mazzara S, Vegliante M, Morello G et al. A Spatially |
| 354 | | Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal |
| 355 | | Center-Related Aggressive B Cell Lymphomas. iScience. 2020 Sep 16;23(10):101562. |
| 330 357 | | doi: 10.1010/J.18c1.2020.101562. PMID: 55085750; PMCID: PMC7522121. |
| 358 | 8. | Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al. Limma powers differential |
| 359 | | expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. |
| 360 | | 2015 Apr 20;43(7):e47. doi: 10.1093/nar/gkv007. Epub 2015 Jan 20. PMID: |
| 361 | | 25605792; PMCID: PMC4402510. |
| 362 | 9. | Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, Patmore R et al. Whole genome |
| 363 | | expression profiling based on paraffin embedded tissue can be used to classify diffuse |
| 364 | | large B-cell lymphoma and predict clinical outcome. Br J Haematol. 2012 |
| 366 | | Nov, 159(4).441-55. doi: 10.1111/bjii.12045. Epub 2012 Sep 15. PMID. 22970711. |
| 367 | 10. | Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T et al. Molecular High- |
| 368 | | Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different |
| 369 | | Approaches to Therapy. J Clin Oncol. 2019 Jan 20;37(3):202-212. doi: |
| 370 | | 10.1200/JCO.18.01314. Epub 2018 Dec 3. Erratum in: J Clin Oncol. 2019 Apr |
| 5/1 | | 20;37(12):1035. PMID: 30523719; PMCID: PMC6338391. |

| 372 | | |
|------------|-----|--|
| 373 | 11. | Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C et al. The B-cell |
| 374 | | receptor controls fitness of MYC-driven lymphoma cells via GSK3ß inhibition. Nature. |
| 375 | | 2017 Jun 8:546(7657):302-306. doi: 10.1038/nature22353. Epub 2017 May 31. PMID: |
| 376 | | 28562582 |
| 377 | | |
| 378 | 12 | Tarte K Zhan F De Vos I Klein B Shaughnessy I Ir Gene expression profiling of |
| 370 | 12. | plasma calls and plasmablasts: toward a batter understanding of the late stages of P |
| 280 | | plasma cells and plasmablasis. loward a better understanding of the fate stages of B- |
| 38U 291 | | 2161 Envit 2002 Mar 27 DMID: 12662452 |
| 202 | | 5101. Epud 2005 Mar 27. PMID: 12005452. |
| 382 | 10 | |
| 383 | 13. | De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of IRF4 in late germinal |
| 384 | | center B-cell differentiation. Immunol Rev. 2012 May;24/(1):/3-92. doi: |
| 385 | | 10.1111/j.1600-065X.2012.01113.x. PMID: 22500833. |
| 386 | | |
| 387 | 14. | Sonja Boy, Marlene van Heerden, Roger Pool, Pascale Willem & Tomas Slavik. |
| 388 | | Plasmablastic lymphoma versus diffuse large B cell lymphoma with plasmablastic |
| 389 | | differentiation: proposal for a novel diagnostic scoring system. Journal of |
| 390 | | Hematopathology volume 8, pages 3–11 (2015). DOI 10.1007/s12308-014-0227-y. |
| 391 | | |
| 392 | 15. | O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. BCMA |
| 393 | | is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 |
| 394 | | Jan 5:199(1):91-8. doi: 10.1084/iem.20031330. PMID: 14707116; PMCID: |
| 395 | | PMC1887725. |
| 396 | | |
| 397 | 16 | Jourdan M. Caraux A. Caron G. Robert N. Fiol G. Rème T et al. Characterization of a |
| 398 | 10. | transitional preplasmablast population in the process of human R cell to plasma cell |
| 399 | | differentiation I Immunol 2011 Oct 15:187(8):3931-41 doi: |
| 400 | | 10.4040/jimmunol 1101230 Enub 2011 Sen 14 PMID: 21018187 |
| 400 | | 10.4049/Jillindiol.1101230. Epub 2011 Sep 14. 1 MilD. 21910107. |
| 401 | 17 | Voor SO Thong V. Lee IV. Sponsor N. Vo D. Choi VS. CD0 is a novel marker for |
| 402 | 1/. | room SO, Zhang A, Lee II, Spencer N, VOF, Chor IS. CD9 is a nover marker for |
| 403 | | 2012 Esh 1.421(1).41 6 dai: 10.1016/j.html 2012.12.102 Erwh 2012 Lag 2 DMID: |
| 404 | | 2015 Feb 1;451(1):41-0. doi: 10.1010/j.bbrc.2012.12.102. Epub 2015 Jan 5. PMID: |
| 405 | | 23291167; PMCID: PMC3563937. |
| 406 | 10 | |
| 407 | 18. | Won WJ, Kearney JF. CD9 is a unique marker for marginal zone B cells, BI cells, and |
| 408 | | plasma cells in mice. J Immunol. 2002 Jun 1;168(11):5605-11. doi: |
| 409 | | 10.4049/jimmunol.168.11.5605. PMID: 12023357. |
| 410 | | |
| 411 | 19. | Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V et al. Loss of |
| 412 | | PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like |
| 413 | | diffuse large B-cell lymphoma Leukemia 2017 Mar 31(3):625-636 doi: |
| 113 | | 10.1028/Jou 2016 2/2 Epub 2016 Aug 20 DMID: 27568520: DMCID: DMC5827850 |
| 414 | | 10.1036/ieu.2010.245. Epud 2010 Aug 25. FMID. 27508520, FMCID. FMC5857855. |
| 415 | • | |
| 416 | 20. | Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. |
| 417 | | Confirmation of the molecular classification of diffuse large B-cell lymphoma by |
| 418 | | immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275-82. |
| 419 | | doi: 10.1182/blood-2003-05-1545, Epub 2003 Sep 22, PMID: 14504078. |
| 420 | | |
| T20 | | |

- 421 21. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H. et al. WHO
 422 Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed.;
 423 IARC: Lyon, France, 2017.
- 425 22. Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X et al. Transcriptome
 426 sequencing reveals a profile that corresponds to genomic variants in Waldenström
 427 macroglobulinemia. Blood. 2016 Aug 11;128(6):827-38. doi: 10.1182/blood-2016-03428 708263. Epub 2016 Jun 14. PMID: 27301862; PMCID: PMC4982454.
- 430 23. Maezawa Y, Nakajima H, Suzuki K, Tamachi T, Ikeda K, Inoue J et al. Involvement of
 431 TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol. 2006 Jan
 432 15;176(2):1013-8. doi: 10.4049/jimmunol.176.2.1013. PMID: 16393988.
- 434
 434 24. Ahonen C, Manning E, Erickson LD, O'Connor B, Lind EF, Pullen SS et al. The CD40435 TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.
 436 Nat Immunol. 2002 May;3(5):451-6. doi: 10.1038/ni792. Epub 2002 Apr 22. PMID:
 437 11967542; PMCID: PMC2834483.
- 439 25. Green JA, Cyster JG. S1PR2 links germinal center confinement and growth regulation.
 440 Immunol Rev. 2012 May;247(1):36-51. doi: 10.1111/j.1600-065X.2012.01114.x.
 441 PMID: 22500830; PMCID: PMC3335345.
- 443 26. Myers RC, King RG, Carter RH, Justement LB. Lymphotoxin α1β2 expression on B
 444 cells is required for follicular dendritic cell activation during the germinal center
 445 response. Eur J Immunol. 2013 Feb;43(2):348-59. doi: 10.1002/eji.201242471. Epub
 446 2012 Dec 5. PMID: 23112125; PMCID: PMC3753018.
- 448 27. Gars E, Butzmann A, Ohgami R, Balakrishna JP, O'Malley DP. The life and death of
 449 the germinal center. Ann Diagn Pathol. 2020 Feb;44:151421. doi:
 450 10.1016/j.anndiagpath.2019.151421. Epub 2019 Nov 13. PMID: 31751845.
- 452 28. Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM et al. A
 453 Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell
 454 Lymphoma with Therapeutic Implications. Cancer Cell. 2020 Apr 13;37(4):551455 568.e14. doi: 10.1016/j.ccell.2020.03.015. PMID: 32289277.
- 29. Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z et al. 457 458 Clinical and Biological Subtypes of B-cell Lymphoma Revealed by 459 Microenvironmental Signatures. Cancer Discov. 2021 Jun;11(6):1468-1489. doi: 10.1158/2159-8290.CD-20-0839. Epub 2021 Feb 4. PMID: 33541860; PMCID: 460 461 PMC8178179.
- 462 463 464

424

429

433

438

442

447

451

456

466 FIGURE LEGENDS

467 Figure 1

468 A, Digitalized slide selection of the Haematocylin and Eosin (H&E)-stained section of the 469 tonsil highlighting the presence of an aberrantly expanded germinal center (asterisk) 470 characterized by the presence of elements with plasmacytoid morphology (inset). On the H&E, 471 representative regions relative to germinal center dark zone (DZ) and light zone (LZ) areas, 472 peri-follicular (Peri) areas, and germinotropic plasmablastic expansion (GEx) areas, are highlighted. Original magnification x50. B, Comparative analysis of H&E and IHC for Bcl-2, 473 474 Bcl-6, CD3, CD20, Kappa and Lambda light chain, Ki67, IRF4, IRF4/CD10, CD2, CD138 in 475 the DZ, LZ, Peri and GEx areas highlighted in A. C, Heatmap of the average expression of the 476 quantitative immunohistochemical analysis of the markers evaluated in the DZ, LZ, Peri, and 477 GEx areas highlighted in B.

478

479 **Figure 2**

480 A, Two-dimensional principal component reduction of the DZ (n=5), LZ (n=5), Peri (n=5), and 481 GEx (n=9) regions of interest (ROIs) profiles according to Digital Spatial Profiling of 1824 482 genes. B, Unsupervised hierarchical clustering of the 24 ROIs. C, Venn diagram of UP-483 modulated genes from three different comparisons (i.e., GEx vs DZ, GEx vs LZ, and GEx vs 484 Peri). D, Venn diagram of DOWN modulated genes from three different comparisons (i.e., 485 GEx vs DZ, GEx vs LZ, and GEx vs Peri). E, GEx signature genes. These genes are 486 significantly differentially expressed in GEx in each comparison. F, Heatmap of differentially 487 expressed genes in GEx as compared to DZ, LZ and Peri ROIs. The GEx signature shows a 488 high discriminatory capacity between GEx ROIs and the other regions.

489

490 Figure 3

491 A, Unsupervised clustering analysis of the 1147 DLBCL cases based on the GEx signature. 492 The signature identifies two distinct clusters; the blue one is characterized by a higher gene 493 expression, while a lower gene expression characterizes the green one. **B**, Survival analysis on 494 the two groups of DLBCL cases obtained from the unsupervised clustering. The overall 495 survival is significantly lower in the group characterized by the higher GEx signature 496 expression. The inset panel reports the cumulative distributions of the total GEx signature 497 expression per patient in the two groups (Kolmogorov-Smirnov p-value < 10e-10). C, Survival 498 analysis on the two groups – Q1 and Q4 - of DLBCL cases selected according to the cumulative 499 distribution of the total GEx signature. The first and the fourth quartiles identify the Q1 and Q4 500 groups, respectively. **D**, Survival analysis on the Q1 and Q4 groups of ABC-DLBCL cases. **E**, 501 Survival analysis on the Q1 and Q4 groups of GCB-DLBCL cases.

Figure 1







С

В

Figure 2



Figure 3

